Stent placement in the superficial femoral and proximal popliteal arteries with the innova self‐expanding bare metal stent system

Objectives The SuperNOVA trial was designed to evaluate performance of the Innova Vascular Self‐Expanding Stent System (Boston Scientific, Marlborough, MA) for treating lesions in the femoropopliteal arteries. Methods Patients with chronic lower limb peripheral artery disease (Rutherford category 2, 3, or 4) and atherosclerotic lesions in the native superficial femoral and/or proximal popliteal artery (lengths 30–190 mm) were enrolled in this single‐arm, multinational study. Major adverse events (MAEs) were defined as all‐cause death through 1 month, target limb major amputation, and target lesion revascularization (TLR). Vessel primary patency was defined as core laboratory‐adjudicated duplex ultrasonography‐derived peak systolic velocity ratio ≤2.4 in the absence of TLR, surgical bypass of the target lesion, or major amputation of the target limb. Primary safety and efficacy endpoints were evaluated at 12 months, with follow‐up through 24 months also reported. Results SuperNOVA patients (N = 299; mean age 67.4 ± 9.7 years, 74% men, 41% with diabetes) had a mean lesion length of 93.2 mm. The MAE‐free rate was 99.7% at 30 days, 85.8% at 12 months, and 77% at 24 months. Kaplan–Meier estimates of primary patency and TLR‐free rates were 68.7% and 78.0%, respectively, at 24 months. Clinical improvements were sustained through 2 years, with 80% of patients displaying no or minimal symptoms (Rutherford category 0–1) at 24 months. Conclusions In the SuperNOVA study, the Innova Stent System demonstrated an excellent safety profile and acceptable clinical outcomes despite the challenging anatomical characteristics of the lesions. © 2017 Wiley Periodicals, Inc.